|1.||Kirchhofer, Daniel: 6 articles (03/2012 - 03/2005)|
|2.||Wu, Qingyu: 5 articles (04/2015 - 04/2006)|
|3.||Kodama, Junichi: 5 articles (09/2010 - 02/2006)|
|4.||Hiramatsu, Yuji: 5 articles (09/2010 - 02/2006)|
|5.||Nasu, Yasutomo: 5 articles (09/2010 - 02/2006)|
|6.||Hongo, Atsushi: 5 articles (09/2010 - 02/2006)|
|7.||Nakamura, Keiichiro: 5 articles (09/2010 - 02/2006)|
|8.||Kumon, Hiromi: 5 articles (09/2010 - 02/2006)|
|9.||Vasioukhin, Valeri: 4 articles (03/2014 - 08/2004)|
|10.||Ganesan, Rajkumar: 4 articles (03/2012 - 11/2008)|
|1.||Prostatic Neoplasms (Prostate Cancer)
10/01/2015 - "This work indicates that the Wnt/β-catenin pathway and the Hepsin pathway act in concert to promote prostate cancer progression. "
10/01/2015 - "To determine whether the overexpression of the prostate oncogene Hepsin could cause prostate cancer progression, we crossed a prostate-specific Hepsin overexpression model to a prostate-specific Apc-deletion model and classified the observed phenotype. "
04/01/2015 - "Hepsin inhibits CDK11p58 IRES activity by suppressing unr expression and eIF-2α phosphorylation in prostate cancer."
04/01/2015 - "While Hepsin alone was not of predictive value, the Hepsin:PCA3 ratio together with serum PSA, expressed as a univariate composite score based on multivariate logistic regression, was shown to be a better predictor than PSA alone of prostate cancer status (AUC 0.724 vs. 0.676) and risk, using D'Amico (AUC 0.701 vs. 0.680) and PRIAS (AUC 0.679 vs. 0.659) risk stratification criteria as classified using prostate biopsies. "
12/01/2012 - "HEPSIN (HPN) gene is one of the most consistently overexpressed genes in patients with prostate cancer; furthermore, there is some evidence supporting an association between HPN gene variants and the risk of developing prostate cancer. "
01/01/2015 - "There were no correlations between AMACR levels, hepsin levels, tumor stage and Gleason score. "
01/01/2015 - "Urinary levels of AMACR and hepsin were determined by ELISA and related to the tumor stage, Gleason score and PSA level. "
08/01/2014 - "To facilitate selective drug delivery to hepsin (Hpn)-expressing cancer cells, the RIPL peptide (IPLVVPLRRRRRRRRC; 16mer; 2.1 kDa) was synthesized as a novel cell penetrating/homing peptide (CPHP) and conjugated to a liposomal carrier. "
07/01/2012 - "Inhibition of hepsin activity suppresses the invasive growth of the tumor. "
03/01/2012 - "Antibody-25 should be valuable for investigating hepsin's role in cancer progression and for potential therapeutic applications. "
|3.||Neoplasm Metastasis (Metastasis)
04/01/2007 - "There was a trend of higher hepsin expression in RCC with distant metastasis, and Kaplan-Meier survival curves showed that high hepsin expression was associated with reduced overall survival (P<0.01, log-rank test). "
03/15/2014 - "These findings indicate that inhibition of Hepsin with small-molecule compounds could provide an effective tool for attenuation of prostate cancer progression and metastasis. "
11/01/2012 - "Our findings show that the maintenance of hepatic structural homeostasis occurs through HGF/c-Met/connexin signaling by hepsin, and hepsin-mediated changes in liver architecture significantly enhance tumor metastasis to the liver."
03/15/2012 - "Overexpression of hepsin has been found to correlate with tumour progression and metastasis, which is so far best studied for prostate cancer, where more than 90% of such tumours show this characteristic. "
05/01/2010 - "Although we did not detect any metastases from the prostates in either the PB-hepsin/PB-Hi-myc or the PB-Hi-myc mice, our data suggests that hepsin and myc cooperate during the progression to high-grade prostatic adenocarcinoma."
|4.||Ovarian Neoplasms (Ovarian Cancer)
02/01/2006 - "Our findings in this study identify Hepsin as a target for new approaches in ovarian cancer treatment."
10/01/2011 - "Additionally, hepsin was identified as a gelatinolytic target in ovarian cancer cells. "
11/01/2008 - "Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model."
02/01/2006 - "Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines."
11/01/2008 - "To gain insight into its function in ovarian cancer, we analyzed the expression and subcellular localization of hepsin protein in ovarian cancer cell lines and tumors. "
|5.||Hepatocellular Carcinoma (Hepatoma)
09/01/2006 - "Decreased expressions of hepsin in human hepatocellular carcinomas."
09/01/2006 - "Quantitative real-time RT-PCR was used to investigate the expression levels of hepsin in a total of 50 paired hepatocellular carcinomas (HCCs) and the corresponding non-tumor liver tissues. "
08/01/2003 - "Reverse-transcription PCR and in-situ -hybridization analysis indicated that m-matriptase-2 expression overlaps with the distribution of mouse hepsin (m-hepsin, a cell-surface serine protease identified in hepatoma cells) in adult tissues and during embryonic development. "
08/01/1993 - "When hepatoma cells were treated with anti-hepsin antibodies, their growth was substantially arrested, suggesting the requirement of hepsin molecules present at the cell surface for normal cell growth. "
02/09/1988 - "A novel trypsin-like serine protease (hepsin) with a putative transmembrane domain expressed by human liver and hepatoma cells."
|1.||Serine Proteases (Serine Protease)
|2.||Complementary DNA (cDNA)
|4.||Peptide Hydrolases (Proteases)
|5.||Messenger RNA (mRNA)
|7.||Biological Markers (Surrogate Marker)
|8.||Coenzyme A (CoA)
|1.||Prostatectomy (Retropubic Prostatectomy)
|2.||Heterologous Transplantation (Xenotransplantation)